Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 19/20 | 0.81 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.72 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.72 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.72 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.72 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.72 |
| ▸ | MTOR | P42345 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434923 | 1.00 | PIK3CB (0.81) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL948460 | 0.92 | PIK3CB (0.85) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL15029486 | 0.87 | PIK3CB (0.83) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL15029493 | 0.86 | PIK3CB (0.81) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL29434920 | 0.84 | PIK3CB (0.89) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4730034 | 0.84 | PIK3CB (0.89) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4588794 | 0.84 | PIK3CB (0.89) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL29434924 | 0.84 | PIK3CB (0.89) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4585104 | 0.84 | PDCD1 (0.62) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| Zstk-474 SCHEMBL373282 | 0.84 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810100-B | Benzofuran-containing PARP-1 and PI3K dual-target inhibitors | 中国药科大学 | 2022-03-11 | — | — | CN | disclosed |
| EP-2604601-B1 | HETERO RING COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-8912180-B2 | Heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2014-12-16 | — | — | US | disclosed |
| US-8912180-B2 | Heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2014-12-16 | — | — | US | disclosed |
| US-8912180-B2 | Heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2014-12-16 | — | — | US | disclosed |
| EP-2604601-A1 | HETERO RING COMPOUND | Astellas Pharma Inc. (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150364-A1 | HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130150364-A1 | HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| WO-2008032027-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032036-A1 | 6-BENZIMIDAZ0LYL-2-M0RPH0LIN0-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032089-A1 | 4-BENZIMIDAZ0LYL-2-M0RPH0LIN0-6-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032033-A1 | 4-BENZIMIDAZOLYL-2-MORPHOLINO-6-PIPERAZINYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150364-A1 | HETEROCYCLIC COMPOUND | IL2, NFATC1, ICOS | PIK3CB 16/4885PIK3CD 6/4885PIK3CA 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.